Company Ocumension Therapeutics

1477

KYG674111011

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Ocumension Therapeutics

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:25 2024-05-27 am EDT			5-day change	1st Jan Change
6.8 ^HKD	-2.58%		-2.02%	+1.80%

Apr. 15	Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	MT
Apr. 15	Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	CI

Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market.

Number of employees: 444

HKD in Million	2022	Weight	2023	Weight	Delta
Ophthalmic Pharmaceutical Platform 100.0 %	185	100.0 %	272	100.0 %	+47.28%

HKD in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	185	100.0 %	272	100.0 %	+47.28%

Managers	Title	Age	Since
Ye Liu CEO	Chief Executive Officer	53	18-07-31
Tim Ruan DFI	Director of Finance/CFO	38	23-01-11
Dong Hong Chen CTO	Chief Tech/Sci/R&D Officer	53	19-10-27
Zhao Peng Hu BRD	Director/Board Member	51	18-09-02
Ting Chan Chen SEC	Corporate Secretary	30	21-06-30
Qinglei Zuo PRN	Corporate Officer/Principal	40	20-12-31
Hong Ying Liu PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Wei Li BRD	Director/Board Member	52	18-03-31
Yan Ling Cao BRD	Director/Board Member	39	19-06-17
Ting Yuk Wu BRD	Director/Board Member	69	20-06-22
Lian Yong Chen CHM	Chairman	62	18-05-22
Yumeng Wang BRD	Director/Board Member	33	21-03-18
Zhenyu Zhang BRD	Director/Board Member	50	22-04-07
Ye Liu CEO	Chief Executive Officer	53	18-07-31
Zhao Peng Hu BRD	Director/Board Member	51	18-09-02
Yi Ran Huang BRD	Director/Board Member	69	20-06-22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	693,654,850	328,939,975 ( 47.42 %)	0	47.42 %

Name	Equities	%	Valuation
6 Dimensions Capital 18.14 %	126,200,000	18.14 %	116 M $
Suzhou Yunchang Investment Consulting Co. Ltd. 18.14 %	126,200,000	18.14 %	116 M $
Boyu Capital Advisory Co. Ltd. 11.24 %	78,214,230	11.24 %	72 M $
Temasek Holdings Pte Ltd. (Investment Management) 6.784 %	47,193,400	6.784 %	43 M $
Capital Research & Management Co. (World Investors) 4.940 %	34,365,083	4.940 %	32 M $
Ye Liu 4.368 %	30,384,480	4.368 %	28 M $
Zhao Peng Hu 0.5342 %	3,716,165	0.5342 %	3 M $
Zhong Geng Fund Management Co. , Ltd. 0.4505 %	3,133,500	0.4505 %	3 M $
Bosera Asset Management Co., Ltd. 0.3388 %	2,357,000	0.3388 %	2 M $
UBS Asset Management (Hong Kong) Ltd. 0.2928 %	2,036,500	0.2928 %	2 M $

Name	Equities	%	Valuation
EYEPOINT PHARMACEUTICALS, INC. 0.19%	100,221	0.19%	1,619,571 $

Ocumension Therapeutics

No. 1858 Yinzhongnan Road Guoxiang Subdistrict

215000, Suzhou

http://www.ocumension.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.309 CNY

Average target price

8.653 CNY

Spread / Average Target

+37.15%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
OCUMENSION THERAPEUTICS	+1.80%	620M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+31.74%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.44%	205B
ROCHE HOLDING AG	-5.97%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals